Dripmate A/S is registered at the Danish Medicines Agency as a medical device manufacturer under LMST Ref.no 2017053175.
Following the expiration of the contract with the former CEO, the Board has employed Carsten Berger, who will become the new CEO of the company.
Previously, Carsten Berger has been affiliated with the company as a board member from 2nd of January 2008 till 18th of June 2012. Therefore, he has a thorough knowledge of the company as well as its market and product.
Chairman of the Board, Arne Kaae, comments:
“As Chairman of the Board of Dripmate A/S I am pleased that Carsten Berger joins as the new CEO of the company, as he has a very high level of expertise and management experience, including setting up teams and sales organizations in large companies. I am confident that Carsten, with his financial, sales and management capabilities, will be able to position Dripmate in the large export markets where Dripmate belongs. The company is looking forward to a long and successful cooperation with Carsten.”
At the company’s Annual General Meeting on the 25th of May 2017, the composition of the Board was changed, as Bjarne Winther resigned as a result of Chr. Nielsen’s disposal of its shares in the company. New Board members elected; Karsten Lollike, Bo Eklund and Carsten Berger were elected. Arne Kaae and Henrik Oehlenschlæger were re-elected.
Subsequently the Board elected Arne Kaae as Chairman. Arne Kaae has been Chairman of the board since the foundation of the company in 2007.